Menu
Menu
Glenmark Pharmaceuticals has launched its Lacosamide Oral Solution, a bioequivalent to Vimpat® Oral Solution, offering a more affordable treatment option for partial-onset seizures. This new product enhances access to epilepsy care, with the same therapeutic efficacy as the branded version, making it a valuable option for patients and healthcare providers.
Glenmark Pharmaceuticals has reached a $25 million settlement with the US Department of Justice to resolve claims related to generic drug pricing practices. The settlement, which will be paid in installments over five years, underscores the increasing regulatory scrutiny on pharmaceutical pricing. Explore the details of the settlement and its potential impact on Glenmark and the broader industry.